Bimatoprost/timolol
| Combination of | |
|---|---|
| Bimatoprost | Prostaglandin analogue |
| Timolol | Beta blocker |
| Clinical data | |
| Trade names | Ganfort |
| AHFS/Drugs.com | UK Drug Information |
| Routes of administration | Topical (eye drops) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Bimatoprost/timolol, sold under the brand name Ganfort, is a medication for the treatment of open angle glaucoma or ocular hypertension.[1][2]
It was approved for use in the European Union in May 2006.[2]
References
- ^ a b "Ganfort 0.3 mg/ml + 5 mg/ml eye drops, solution - Summary of Product Characteristics (SmPC)". (emc). 20 February 2020. Retrieved 1 March 2020.
- ^ a b "Ganfort EPAR". European Medicines Agency (EMA). 26 February 2020. Retrieved 1 March 2020.
Further reading
- Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL (2012). "Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis". PLoS ONE. 7 (9): e45079. doi:10.1371/journal.pone.0045079. PMC 3441590. PMID 23028770.
- Fang Y, Ling Z, Sun X (2015). "Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol". Drug Des Devel Ther. 9: 2617–25. doi:10.2147/DDDT.S80338. PMC 4435054. PMID 25999695.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - Guven Yilmaz S, Degirmenci C, Karakoyun YE, Yusifov E, Ates H (August 2018). "The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP". Int Ophthalmol. 38 (4): 1425–1431. doi:10.1007/s10792-017-0601-8. PMID 28616797.
- Quaranta L, Biagioli E, Riva I, Rulli E, Poli D, Katsanos A, Floriani I (May 2013). "Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis". J Ocul Pharmacol Ther. 29 (4): 382–9. doi:10.1089/jop.2012.0186. hdl:11379/277321. PMID 23231442.
- Xing Y, Zhu L, Zhang K, Huang S (2020). "The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis". PLoS ONE. 15 (2): e0229682. doi:10.1371/journal.pone.0229682. PMID 32106236.
External links
- "Bimatoprost". Drug Information Portal. U.S. National Library of Medicine.
- "Timolol Ophthalmic". Drug Information Portal. U.S. National Library of Medicine.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |